Opiant Pharmaceuticals Inc. (OPNT) |
|
28.8 1.73 (6.39%)
|
01-19 08:31 |
|
Open: |
26.69 |
Pre. Close: |
27.07 |
|
High:
|
28.99 |
Low:
|
26.66 |
|
Volume:
|
83,455 |
Market Cap:
|
136M |
|
|
|
|
Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes medicines for the treatment for opioid overdose reversal; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Santa Monica, California. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
29.072 - 29.233 |
29.233 - 29.364 |
|
Low:
|
26.19 - 26.405 |
26.405 - 26.58 |
|
Close:
|
28.46 - 28.803 |
28.803 - 29.081 |
|
Technical analysis |
as of: 2022-01-19 8:23:23 AM |
|
Overall:
|
 |
| Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 38.55 One year: 44.05 |
| Support: |
Support1: 25.40 Support2: 21.13 |
| Resistance: |
Resistance1: 33.01 Resistance2: 37.71 |
| Pivot: |
31.35  |
| Moving Average: |
MA(5): 28.91 MA(20): 32.25
MA(100): 26.67  MA(250): 18.66 |
| MACD: |
MACD(12,26): -0.60 Signal(9): 0.15 |
| Stochastic oscillator: |
%K(14,3): 28.25 %D(3): 19.85 |
| RSI: |
RSI(14): 41.50 |
| 52-week: |
High: 37.71 Low: 9.82 Change(%): 186.6 |
| Average Vol(K): |
3-Month: 6381 10-Days: 7246 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.OPNT has closed above bottom band by 18.3%. Bollinger Bands are 16.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Mon, 17 Jan 2022
CARsgen Appoints Richard John Daly as the President of CARsgen Therapeutics Corporation - Yahoo Finance
Sun, 16 Jan 2022
Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Expected to Announce Quarterly Sales of $13.68 Million - MarketBeat
Mon, 03 Jan 2022
Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Short Interest Up 67.1% in December - MarketBeat
Mon, 20 Dec 2021
Opiant Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Thu, 11 Nov 2021
Opiant Pharmaceuticals Announces Third Quarter 2021 Financial Results and Provides Corporate Update - Yahoo Finance
Wed, 10 Nov 2021
Opiant Pharmaceuticals to present at Jefferies Virtual London Healthcare Conference - GlobeNewswire
|
Financial Analysis |
| Growth |
n/a |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
n/a |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Neutral |
Price to Earnings: |
Outperform |
| Return on Equity: |
Neutral |
Debt to Equity: |
Outperform |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
5 |
| Shares Float (M) |
4 |
|
% Held by Insiders
|
8.50 |
|
% Held by Institutions
|
30.03 |
|
Shares Short (K)
|
27 |
|
Shares Short P. Month (K)
|
16 |
Stock Financials |
|
EPS
|
0.310 |
|
EPS Est This Year
|
0.500 |
|
EPS Est Next Year
|
1.250 |
|
Book Value (p.s.)
|
9.100 |
|
Profit Margin
|
3.58 |
|
Operating Margin
|
6.53 |
|
Return on Assets (ttm)
|
3.2 |
|
Return on Equity (ttm)
|
4.1 |
|
Qtrly Rev. Growth
|
79.4 |
|
Gross Profit (p.s.)
|
3.006 |
|
Sales Per Share
|
9.303 |
|
EBITDA (p.s.)
|
0.631 |
|
Qtrly Earnings Growth
|
371.30 |
|
Operating Cash Flow (M)
|
-2 |
|
Levered Free Cash Flow (M)
|
-4 |
Stock Valuations |
|
PE Ratio
|
92.90 |
|
PEG Ratio
|
|
|
Price to Book value
|
3.16 |
|
Price to Sales
|
3.10 |
|
Price to Cash Flow
|
-79.49 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
